Chimeric (α/β + α)-peptide ligands for the BH3-recognition cleft of Bcl-xL: Critical role of the molecular scaffold in protein surface recognition

Journal of the American Chemical Society

Volumn 127, Issue 34, 2005, Pages 11966-11968

  Sadowsky, Jack D ^a   Schmitt, Margaret A ^a   Lee, Hee Seung ^a,d   Umezawa, Naoki ^a,e   Wang, Shaomeng ^b   Tomita, York ^c   Gellman, Samuel H ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CHIMERIC PROTEIN; LIGAND; PROTEIN BCL XL;

ALPHA HELIX; ARTICLE; BETA CHAIN; BINDING AFFINITY; BINDING SITE; CHIMERA; MOLECULAR RECOGNITION; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION;

BINDING, COMPETITIVE; LIGANDS; MEMBRANE PROTEINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; STEREOISOMERISM;

EID: 24144488383     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja053678t     Document Type: Article

References (38)

1. (a) Arkin, M. R.; Wells, J. A. Nat. Rev. Drug Discovery 2004, 3, 301-317.
2. (b) Cochran, A. G. Chem. Biol. 2000, 7, R85-R94.
3. (c) Gadek, T. R.; Nicholas, J. B. Biochem. Pharmacol. 2003, 65, 1-8.
4. (d) Berg, T. Angew. Chem., Int. Ed. 2003, 42, 2462-2481.
5. (e) Peczuh, M. W.; Hamilton, A. D. Chem. Rev. 2000, 100, 2479-2494.
6. (a) Arkin, M. R.; Randal, M.; DeLano, W. L.; Hyde, J.; Luong, T. N.; Oslob, J. D.; Raphael, D. R.; Taylor, L.; Wang, J.; McDowell, R. S.; Wells, J. A.; Braisted, A. C. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 1603-1608.
7. (b) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. Science 2004, 303, 844-848.
8. (c) Oltersdorf, T., et al. Nature 2005, 435, 677-681.
9. (a) Werder, M.; Hauser, H.; Abele, S.; Seebach, D. Helv. Chim. Acta 1999, 82, 1774-1783.
10. (b) Lee, H.-S.; Syud, F. A.; Wang, X.; Gellman, S. H. J. Am. Chem. Soc. 2001, 123, 7721-7722.
11. (c) Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. Angew. Chem., Int. Ed. 2003, 42, 535-539.
12. (d) Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. J. Am. Chem. Soc. 2004, 126, 9468-9469.
13. Petros, A. M.; Olejniczak, E. T.; Fesik, S. W. Biochim. Biophys. Acta 2004, 1644, 83-94.
14. (a) Adams, J. M.; Cory, S. Science 1998, 281, 1322-1326.
15. (b) Coultas, L.; Strasser, A. Semin. Cancer Biol. 2003, 13, 115-123.
16. (c) Letai, A.; Bassik, M. C.; Walensky, L. D.; Sorcinelli, M. D.; Weiler, S.; Korsmeyer, S. J. Cancer Cell 2002, 2, 183-192.
17. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Science 1997, 275, 983-986.
18. L inhibition: (a) Baell, J. B.; Huang, D. C. S. Biochem. Pharmacol. 2002, 64, 851-863.
19. (b) O'Neill, J.; Manion, M.; Schwartz, P.; Hockenbery, D. M. Biochim. Biophys. Acta 2004, 1705, 43-51.
20. i = 0.1 μM, see: Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; Hamilton, A. D. J. Am. Chem. Soc. 2002, 124, 11838-11839.
21. (a) Petros, A. M.; Nettesheim, D. G.; Wang, Y.; Olejniczak, E. T.; Meadows, R. P.; Mack, J.; Swift, K.; Matayoshi, E. D.; Zhang, H.; Thompson, C. B.; Fesik, S. W. Protein Sci. 2000, 9, 2528-2534.
22. (b) Walensky, L. D.; Kung, A. L.: Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Science 2004, 305, 1466-1470.
23. (c) Gemperli, A. C.; Rutledge, S. E.; Maranda, A.; Schepartz, A. J. Am. Chem. Soc. 2005, 127, 1596-1597.
24. Frackenpohl, J.; Arvidsson, P. I.; Schreiber, J. V.; Seebach, D. ChemBioChem 2001, 2, 445-455.
25. Cheng, R. P.; Gellman, S. H.; DeGrado, W. F. Chem. Rev. 2001, 101, 3219-3232.
26. L. See Supporting Information for details.
27. (a) Hayen, A.; Schmitt, M. A.; Ngassa, F. N.; Thomasson, K. A.; Gellman, S. H. Angew. Chem., Int. Ed. 2004, 43, 505-510.
28. See also: (b) De Pol, S.; Zorn, C.; Klein, C. D.; Zerbe, O.; Reiser, O. Angew. Chem., Int. Ed. 2004, 43, 511-514.
29. L] = 20 nM.
30. i for unlabeled Bak 16-mer is similar to the reported value: Zhang, H.; Nimmer, P.; Rosenberg, S. H.; Ng, S.; Joseph, M. Anal. Biochem. 2002, 307, 70-75.
31. Rapid proteolysis of the α-peptide segment of 2 is observed upon treatment with Pronase, while the α/β segment remains intact for at least 24 h.
32. 50 of 120 μM in the FP assay, suggesting that the α/β portions of 2 and 4 target the BH3 binding site and contribute substantially to binding.
33. (a) Ali, M.; Smith, L. M.; Feeney, R. E. Biochim. Biophys. Acta 1969, 194, 256-264.
34. (b) Church, W. R.; Rawitch, A. B.; Ebner, K. E. Arch. Biochem. Biophys. 1981, 206, 285-290.
35. Alizadeh-Pasdar, N.; Li-Chan, E. C. Y. J. Agric. Food Chem. 2000, 48, 328-334.
36. Among α- and β-peptides, alcohol solvents are known to promote secondary structure relative to water; the folding observed in such organic solvents generally reflects the conformational propensities in water, (a) Luo, P.; Baldwin, R. L. Biochemistry 1997, 36, 8413-8421.
37. (b) Abele, S.; Guichard, G.; Seebach, D. Helv. Chim. Acta 1998, 81, 2141-2156.
38. (c) Arvidsson, P. I.; Rueping, M.; Seebach, D. J. Chem. Soc., Chem. Commun. 2001, 649-650.